TY - JOUR
T1 - Cost-effectiveness analysis of ceftriaxone generic and patent in children with typhoid
AU - Sari, Santi Purna
AU - Putri, Icut Diki Adestia
AU - Nursanti, Binar
N1 - Publisher Copyright:
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Objective: This study aimed to measure and compare the effectivity and cost of the two types of ceftriaxone to determine the more cost-effective treatment. Methods: In a cross-sectional analytical study, prescription and administrative financial data were retrospectively collected using the total sampling method. Data of 63 patients, comprising 43 and 20 patients treated with generic and patent ceftriaxone, respectively, were analyzed. The effectiveness of the treatment was measured in terms of the length of hospital stay of the patients. The total cost of the treatment was the total median of the costs of drugs, laboratory examinations, medical device usage, physician service, and hospitalization. Results: The effectiveness of both generic and patent ceftriaxone was 4 days of hospital stay. Cost-effectiveness ratio of generic ceftriaxone was Rp 575,937.25/day and that of patent ceftriaxone was Rp 888,601.75/day. Conclusion: Generic ceftriaxone was more cost-effective than patent ceftriaxone.
AB - Objective: This study aimed to measure and compare the effectivity and cost of the two types of ceftriaxone to determine the more cost-effective treatment. Methods: In a cross-sectional analytical study, prescription and administrative financial data were retrospectively collected using the total sampling method. Data of 63 patients, comprising 43 and 20 patients treated with generic and patent ceftriaxone, respectively, were analyzed. The effectiveness of the treatment was measured in terms of the length of hospital stay of the patients. The total cost of the treatment was the total median of the costs of drugs, laboratory examinations, medical device usage, physician service, and hospitalization. Results: The effectiveness of both generic and patent ceftriaxone was 4 days of hospital stay. Cost-effectiveness ratio of generic ceftriaxone was Rp 575,937.25/day and that of patent ceftriaxone was Rp 888,601.75/day. Conclusion: Generic ceftriaxone was more cost-effective than patent ceftriaxone.
KW - Ceftriaxone
KW - Cost-effectiveness analysis
KW - Karya bhakti Pratiwi Hospital
KW - Pharmacoeconomic
KW - Typhoid fever
UR - http://www.scopus.com/inward/record.url?scp=85071872782&partnerID=8YFLogxK
U2 - 10.22159/ijap.2018.v10s1.16
DO - 10.22159/ijap.2018.v10s1.16
M3 - Article
AN - SCOPUS:85071872782
SN - 0975-7058
VL - 10
SP - 76
EP - 80
JO - International Journal of Applied Pharmaceutics
JF - International Journal of Applied Pharmaceutics
IS - Special Issue 1
ER -
